Articles tagged with Vaccine Development
A new biodegradable polymer-based delivery system efficiently transports mRNA, outperforming existing lipid nanoparticles in delivery efficiency and expression duration. The study also shows improved immune response results without liver accumulation or toxicity.
A broadly neutralizing antibody has been shown to protect monkeys against severe H5N1 avian flu disease. The antibody's stable structure ensures it can withstand virus variants, providing universal protection against a globally spreading airborne infection. Serum levels of the antibody remained stable for up to 12 weeks.
Researchers developed a new approach to quickly identify mutations that enable viral immune escape. By analyzing the effects of individual mutations in reverse, they found three key mutations in the spike protein responsible for immune evasion.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
Researchers at the University of Queensland have identified a new henipavirus, Camp Hill virus, in shrews in Alabama, USA. The discovery suggests these viruses may be more globally distributed than previously thought, with implications for human health and vaccine development.
The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.
Researchers developed MUNIS, a deep learning tool that predicts CD8+ T cell epitopes with high accuracy, potentially accelerating vaccine development. The tool was validated using experimental data from influenza, HIV, and EBV, demonstrating its potential to streamline vaccine design.
Southwest Research Institute's Risk Evaluation & Medical Decision Efficacy (REMEDY) tool supports agile medical decisions on countermeasures for chemical and biological threats. The REMEDY mission risk evaluations quantify risks and benefits of medical countermeasures, enabling operational planners to make informed decisions.
Researchers at Terasaki Institute develop lipopeptide hydrogels to deliver peptide-based cancer vaccines, demonstrating sustained release and enhanced immune cell uptake. The system shows promise in overcoming limitations of traditional peptide-based vaccines.
Researchers develop BEND lipids to improve LNP mRNA delivery and gene editing by breaking through the endosomal membrane. The new lipids outperform existing LNPs used in COVID-19 vaccines, with improved efficacy rates up to tenfold.
A West Virginia University legal scholar argues that current laws favor biologic drugs with longer exclusivity periods, affecting their pricing. The scholar suggests reducing exclusivity for biologics to bring them in line with small-molecule drugs, which could lower drug costs.
Cancer vaccines hold transformative potential, leveraging neoantigens to activate the immune system against tumors. UK researchers are positioning themselves for a strategic shift in cancer vaccine trials, recognizing opportunities for improvement.
A novel diagnostic system called TwinDemic Detection offers simultaneous and rapid detection of SARS-CoV-2 and influenza A virus. The system has a detection limit of 0.46 picomolar for CoV and 0.39 pM for IAV, correctly predicting positive and negative samples in high percentages.
Researchers at the University of São Paulo's Medical School have developed a COVID-19 vaccine using virus-like particles (VLPs), which proved highly protective, safe, and versatile in animal trials. The vaccine can be easily updated to combat variants of concern without requiring an adjuvant.
A new self-destructing vaccine provides improved safety and protection against TB in macaque monkeys, outperforming the standard BCG vaccine. The 'kill switch' mechanism eliminates the risk of accidental infection, offering a safer vaccination option for immunocompromised individuals.
Scientists discovered that T cells can prevent acute viral infections, challenging traditional views on sterilising immunity and herd immunity. The study found that T cells controlled viral loads and antibodies produced, and were effective in preventing infection to undetectable levels in some participants.
Researchers at the University of Gothenburg have discovered an antibody-like molecule, E10, that can protect mice from various influenza viruses. The molecule targets a conserved part of the virus's surface protein shared across multiple influenza types, providing effective protection against seasonal epidemics.
Researchers at NIH have identified a novel class of anti-malaria antibodies that target previously untargeted regions of the parasite. These antibodies have shown promise in providing protection against malaria parasites in animal models and could lead to new prevention methods.
Researchers developed AI-driven therapeutic platform mimicking viral structures to deliver therapeutic genes to target cells. The innovative approach achieved precise symmetrical structures and effectively delivered payloads, paving the way for breakthroughs in gene therapies and next-generation vaccines.
Researchers provide comprehensive review of RSV's virology, clinical impact, and prevention strategies, emphasizing the need for effective vaccines to mitigate this critical health need. The review highlights RSV's severe impact on infants, children, and older adults, as well as its potential effects on multiple organs and systems.
A live-attenuated vaccine against Lassa virus has been developed and shown to be safe and 100% effective in protecting guinea pigs from the virus. The vaccine was created by modifying the genome of the virus to prevent it from causing disease, making it a promising candidate for future clinical trials.
EBViously aims to prevent infectious mononucleosis and secondary diseases such as ME/CFS, while also protecting against certain types of cancer. The company's innovative vaccine candidate uses virus-like particles derived from EBV to trigger a targeted immune response.
Researchers at Washington University in St. Louis are developing vaccines to target misfolded proteins in the brain, with a focus on preventing inflammation and using peptide nanofibers. The goal is to prevent dementia by training the immune system against amyloid beta and tau proteins.
Researchers created an advanced computational model to optimize maternal vaccine design and protect high-risk populations. The model helps reveal which antibodies can pass through effectively and when, enabling the development of safer, more effective vaccines.
Researchers found that antibodies targeting a specific site on the malaria parasite's virulence protein bind to the human host's endothelial protein C receptor, neutralizing the parasite. The discovery provides new insights into prevention and treatment of severe malaria.
The American Heart Association has released its list of top cardiovascular research for 2024, focusing on prevention, treatment and the benefits of anti-obesity medications. The research highlights improvements in assessing cardiovascular risk, identifying early prevention opportunities and treating heart failure.
Researchers found a powerful antioxidant in Deinococcus radiodurans that combines with manganese to protect against radiation damage. The discovery could lead to synthetic antioxidants tailored for human needs, protecting astronauts and preparing for radiation emergencies.
Scientists at The Jackson Laboratory have identified the CAST/EiJ mouse as a highly susceptible model for studying severe COVID-19. This genetically pure background allows researchers to investigate the virus's impact without artificial receptor modifications, mirroring human responses. Initial trials using antiviral treatments show pr...
A novel vaccine design has demonstrated robust immune response and broad neutralization of HCV strains in mouse models. The innovative approach employs epitope-focused immunogens, which could pave the way for an effective HCV vaccine, potentially limiting its global spread.
A team of UCalgary researchers, led by Dr. Anthony Schryvers, has developed a new vaccine to protect cattle from hemorrhagic septicemia, a deadly bacterial disease that destroys livestock and livelihoods. The vaccine is designed with a long-lasting immune response and has been patented.
Researchers have discovered a monoclonal antibody capable of targeting multiple SARS-CoV-2 variants, including recent Omicron strains. K4-66's exceptional ability to adapt to the virus's frequent mutations makes it a promising candidate for vaccine and therapy development.
Researchers at Penn School of Engineering and Applied Science have developed a new method to refine ionizable lipids, key ingredients in lipid nanoparticles. This approach combines precision with rapid output, enabling safer and more effective mRNA vaccines and therapeutics.
Researchers are developing a novel vaccine and exploring the use of bile acids to fight necrotic enteritis, a preventable intestinal disease in poultry that costs the industry up to $6 billion annually. The vaccine, known as MEFA, targets multiple virulence points of the disease-causing pathogen, providing better protection against inf...
Researchers developed an ingestible capsule that releases a burst of drugs into the stomach or other organs, eliminating the need for injections. The capsule uses compressed carbon dioxide or tightly coiled springs to propel liquid drugs out, targeting specific parts of the digestive tract.
Researchers at Scripps Research have analyzed the molecular structure of viral proteins and developed a more stable form to create effective vaccines. The new design may lead to combination vaccines that target both RSV and human metapneumovirus, reducing hospitalizations for vulnerable populations.
Researchers developed a nasal vaccine combining traditional pertussis antigens with an innovative adjuvant called T-vant to boost immune response. The new vaccine was shown to prevent the bacteria's colonization in the respiratory tract, significantly curbing whooping cough spread.
Scientists have developed an experimental vaccine that combines the benefits of both vaccine strategies, using a horsepox virus to confer safety in a single shot. The new vaccine is substantially more attenuated than the vaccinia virus used in existing vaccines, reducing the risk of side effects and triggering systemic infections.
Researchers created tiny lab-grown models of human immune systems to study immune function in cancer and predict disease treatment response. The miniature models support longer cell function, allowing processes like antibody formation to occur similar to the human body.
Researchers at Cleveland Clinic have made significant progress in their novel vaccine aimed at preventing triple-negative breast cancer. The study found that the investigational vaccine was generally well-tolerated and produced an immune response in most patients, with the highest tolerated dose to date identified.
Researchers at Kumamoto University have developed a cutting-edge diagnostic tool, Intelli-OVI, to rapidly identify emerging SARS-CoV-2 variants. This system combines advanced DNA detection technology with computational algorithms to offer a quicker and more cost-effective method of monitoring viral mutations.
Researchers at Argonne National Laboratory have developed an AI-driven protein design framework that uses multimodal data to speed up the design of new proteins. The framework has been selected as a finalist for the prestigious Gordon Bell Prize, recognizing breakthroughs in high-performance computing.
The TEDDY study aims to understand the causes of type 1 diabetes in children, finding a connection between enterovirus infection, autoantibodies, and disease development. Probiotics may also reduce risk in infants at high danger of developing diabetes-related antibodies.
A phase Ib clinical trial has shown that the MVA-MERS-S vaccine candidate is safe and effective in healthy individuals previously infected with SARS-CoV-2. The vaccine was tested in a placebo-controlled study with no serious vaccine-related side effects, indicating promising results.
Researchers at Nagoya University developed an innovative synthesis technology to produce high-purity, fully chemically synthesized mRNA. This breakthrough cuts down the production time and can be used to address concerns about purity and speed in mRNA vaccine development.
A study by Johns Hopkins Medicine found distinct immune 'signatures' in patients who developed adverse events while taking immunotherapy. These signatures, including increases in white blood cells known as Th2 and Th17, predict the development of immune-related adverse events and may be targeted for treatment.
Induced resistance, a plant-based approach, prepares plants to fight pests and disease by activating their immune systems. This holistic strategy combines multiple methods for tailored protection, enhancing abilities beyond just one defense mechanism.
Scientists at St. Jude Children's Research Hospital found that nutrient availability affects T cell development and mitochondrial activity, inhibiting T cell formation in lysosomes. The study highlights the crucial role of organelle signaling, such as mitochondrial and lysosomal function, in shaping tissue immunity.
A new report argues that countries can cut premature mortality in half by 2050 through targeted health investments. By prioritizing the 15 health conditions causing most premature deaths and implementing public subsidies for essential medicines and diagnostics, nations can achieve this goal.
The authors emphasize the importance of increasing vaccination rates to combat decreasing rates globally. They also highlight emerging challenges such as a highly virulent strain of influenza and measles outbreaks, particularly in areas with low vaccination rates.
Scientists at Houston Methodist will focus on developing efficacious vaccines and therapeutic antibodies for viruses in the Nairoviridae, Hantaviridae, and Paramyxoviridae families. The goal is to prepare for potential outbreaks and develop effective medical countermeasures in response to a next pandemic.
Researchers at Houston Methodist are working on a national consortium to develop vaccines against two common and destructive strains of herpesviruses. The project aims to create prophylactic and therapeutic vaccines using a computational toolkit that could transform vaccine development.
Researchers at Karolinska Institutet have identified a new potential risk marker for cardiovascular disease in older women. Low levels of an anti-inflammatory antibody are associated with a higher risk of heart attack and coronary heart disease, independent of other known risk factors.
Researchers at La Jolla Institute for Immunology have developed six lines of humanized mice to study human cases of COVID-19, shedding light on SARS-CoV-2's movement through the body and varying symptoms. The models help understand how different genetic backgrounds influence disease progression.
Researchers have developed an antibody that can identify Campylobacter jejuni and inhibit its growth, reducing pathogenicity. The antibody targets a multiprotein complex essential for the bacteria's energy production, making it a potential target for therapy and vaccination.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
Vanderbilt University Medical Center has joined ReVAMPP, a $100 million program to develop vaccines and antibody therapies against emerging viral threats. The center will focus on nine virus groups that pose the greatest risk to human health, including bunyaviruses and picornaviruses.
Researchers at La Jolla Institute for Immunology have captured the first detailed images of the Ebola virus nucleocapsid structure, which is crucial for replicating in host cells. This breakthrough may accelerate the development of universal antivirals that target this viral structure to combat multiple filoviruses.
Scientists at WashU Medicine are developing strategies and tools to produce vaccines and antibody-based therapies for viruses from five understudied families. The effort aims to rapidly respond to potential future pandemics, with funding totaling $90M over three years.
The development of vaccine adjuvants has evolved significantly, shifting from empirical methods to a more structured approach grounded in rational drug design. This new era emphasizes the importance of understanding structural and functional traits of adjuvants.
Researchers from Thomas Jefferson University and the University of Maryland Baltimore developed a promising new vaccine candidate that protects against Lassa fever. The study demonstrated the vaccine effectively prevents severe cases of the disease and death in preclinical animal models, paving the way for research in people.